CDKN2A and lung adenocarcinoma: In a recent report where the authors performed whole-exome sequencing of brain metastases from lung adenocarcinomas (BM-LUAD) and primary lung adenocarcinomas using case–control analysis to identify genomic alterations that promote BrM, they identified three regions (MYC, YAP1, MMP13) that had significantly higher amplification frequencies and one region (CDKN2A/B) that had higher deletion frequencies in BM-LUAD as compared to primary lung adenocarcinoma (23).